2024-12-14 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**1. Performance Comparison & Divergence:**

Merck & Co Inc (MRK) is a leading pharmaceutical company known for its innovative medicines and vaccines.  Over the analyzed period, MRK's cumulative return (67.60%) significantly underperformed the S&P 500 (VOO) which had a return of 120.91%.  The difference is -53.3%, placing it at the 9.3rd percentile of historical relative performance compared to the S&P 500 based on the provided data's minimum and maximum divergence.


**Alpha and Beta Analysis:**

The provided data shows inconsistent performance relative to the market (S&P 500) as indicated by the fluctuating CAGR and negative alpha values throughout the years.  The high beta values suggest that MRK's stock price is highly sensitive to market movements. Market capitalization (Cap(B)) has steadily increased over the years.


**2. Recent Price Movements:**

* **Closing Price:** $102.0
* **5-Day Moving Average:** $101.56
* **20-Day Moving Average:** $100.58
* **60-Day Moving Average:** $105.14

The price is currently trading slightly below its 5-day and 20-day moving averages but above its 60-day moving average, suggesting a recent period of consolidation or mild downward pressure.


**3. Technical Indicators & Expected Return:**

* **RSI:** 57.92 (Slightly above neutral; neither overbought nor oversold)
* **PPO:** 0.29 (Positive, suggesting bullish momentum)
* **Relative Strength Change (20-day):** -0.4 (Indicates recent weakening of relative strength)
* **Expected Return:** 0.0% (This suggests that, based on the provided data, there is no expected outperformance of the S&P 500 over the long term).  A long-term (2+ years) buy-and-hold strategy would need further analysis beyond the provided data to establish a reasonable expected return relative to the S&P 500.  The 0% figure is likely based solely on the provided data and historical comparison; it's not a prediction of future returns.

The closing price of $102.01 is not significantly different from the moving averages to suggest a dramatic price swing (no sharp up or down movements are indicated).


**4. Recent Earnings Analysis:**

The provided earnings data shows some volatility:

* **Revenue:** Shows relatively stable revenue generation, ranging from $15.78B to $16.66B over the reported quarters with slight fluctuations.  There is no consistent upward or downward trend readily apparent.
* **EPS:** EPS is also inconsistent, fluctuating between $1.25 and $2.15 across the reported quarters, lacking a consistent trend.
* **Notable Beats or Misses:**  Cannot be determined without knowing the market expectations for each quarter's EPS and revenue. The provided data only contains reported figures.


**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue has generally increased, although there's some fluctuation. Profit margins are relatively high and stable, generally above 73%, but are exhibiting a slight downward trend.
* **Capital and Profitability:** Equity has increased over time, with some volatility quarter to quarter. ROE shows considerable fluctuation, even turning negative in one quarter (2023-12-31), indicating potential challenges in profitability during that period.  Generally, high ROE indicates effective use of equity.

**6. News and Recent Issues:**

No news or recent market outlook information are provided.  Analyst opinions are also missing.


**7. Overall Analysis:**

MRK has demonstrated inconsistent performance relative to the S&P 500,  showing periods of both outperformance and underperformance. While the company shows strong revenue and generally high profit margins, the fluctuating EPS and ROE suggest some uncertainty in the near term. Technical indicators present a relatively neutral picture.  More information (analyst expectations, market outlook, recent news) is needed for a more complete evaluation. The 0% expected return relative to the S&P 500, based only on provided data, is not indicative of long-term performance prediction.  Further research is required.


**8.  Disclaimer:** This analysis is based solely on the limited data provided. It is not financial advice and should not be used as the sole basis for investment decisions.  Thorough independent research and consultation with a financial advisor are recommended before making any investment choices.
